To systematically analyze such alterations, we performed whole-exome sequencing of 14 matched normal and metastatic tumor DNAs. Using stringent criteria, we identified 68 genes that appeared to be somatically mutated at elevated frequency, many of which are not known to be genetically altered in tumors. Most importantly, we discovered that TRRAP harbored a recurrent mutation that clustered in one position (p. Ser722Phe) in 6 out of 167 affected individuals (~4%), as well as a previously unidentified gene, GRIN2A, which was mutated in 33% of melanoma samples. The nature, pattern and functional evaluation of the TRRAP recurrent mutation suggest that TRRAP functions as an oncogene. Our study provides, to our knowledge, the most comprehensive map of genetic alterations in melanoma to date and suggests that the glutamate signaling pathway is involved in this disease.
The incidence of melanoma is increasing more than any other cancer, and knowledge of its genetic alterations is limited.
To systematically analyze such alterations, we performed whole-exome sequencing of 14 matched normal and metastatic tumor DNAs. Using stringent criteria, we identified 68 genes that appeared to be somatically mutated at elevated frequency, many of which are not known to be genetically altered in tumors. Most importantly, we discovered that TRRAP harbored a recurrent mutation that clustered in one position (p. Ser722Phe) in 6 out of 167 affected individuals (~4%), as well as a previously unidentified gene, GRIN2A, which was mutated in 33% of melanoma samples. The nature, pattern and functional evaluation of the TRRAP recurrent mutation suggest that TRRAP functions as an oncogene. Our study provides, to our knowledge, the most comprehensive map of genetic alterations in melanoma to date and suggests that the glutamate signaling pathway is involved in this disease.
Approximately 69,000 individuals were diagnosed with invasive melanoma in the United States in 2010, and there were approximately 8,700 deaths from melanoma in that year 1 . New insights into the pathogenesis of this lethal disease are needed. Although candidate gene analyses have been powerful in identifying melanoma mutations, such those in as BRAF, cKit and ERBB4 (refs. 2-4) , and whole-genome sequencing of a single melanoma has been completed 5 , no comprehensive analysis of this tumor type has yet been performed. We have now used whole-exome sequencing to search for additional candidate melanoma genes in an unbiased fashion.
We conducted an exome resequencing of 14 matched normal and metastatic tumor DNAs from untreated individuals with melanoma. We enriched exonic sequences using Agilent's SureSelect technology for targeted exon capture 6 , targeting 37 Mb of sequence from exons and their flanking regions in ~20,000 genes. We performed sequencing with the Illumina GAII platform and aligned the reads using ELAND (Illumina, Inc.) followed by cross_match (see URLs) to the reference human genome (build 36.1). On average, we generated 12 Gb of sequence per sample to a mean depth of 180× or greater to achieve exome builds with at least 90% of the exons covered by high quality genotype calls. To eliminate common germline mutations, we removed any potential somatic mutation that was observed in dbSNP130 or in the 1000 Genomes Project data. To determine which of these alterations were somatic (that is, tumor-specific), we compared these data to the matched normal tissue. From these putative alterations, we identified 5,161 potential somatic mutations in 3,568 different genes in the 14 samples sequenced.
To discriminate true mutations from the possible sequence alterations identified, we applied several steps, described in the Supplementary Note and Supplementary Table 1. These refinements gave us a 97.9% coverage rate, a 2.4% false-negative rate and a sensitivity of 81%. Furthermore, these tools removed ~18% of the alterations, leaving 4,226 putative somatic alterations for further scrutiny. A total of 3,871 alterations were heterozygous, and 355 changes were putative alterations in regions of loss of heterozygosity (Supplementary Table 2) . Of these alterations, 2,813 caused amino acid changes (non-synonymous), including 2,589 missense and 175 nonsense alterations, and 49 occurred at splice sites. There were 1,387 silent (synonymous) substitutions. We observed a total of 18 small deletions and 9 insertions.
The observed somatic mutations could either be 'driver' mutations that have a role in melanoma neoplasia or functionally inert 'passenger' changes. This screen yielded a ratio of non-synonymous to synonymous changes (N:S ratio) of 2.0:1, which is not higher than the N:S ratio of 2.5:1 predicted for non-selected passenger mutations 7 , suggesting that most of these alterations are likely to be 'passenger' mutations. The number of C>T mutations was significantly greater than the numbers of other nucleotide substitutions, resulting in a high prevalence of C>T/G>A transitions (P < 0.001) (Supplementary Fig. 1 ). Finally, we observed a total of 116 dinucleotide substitutions; of these, 59 were CC>TT/GG>AA changes, all consistent with the previously documented ultraviolet light exposure signature 8 .
To search for new recurrent mutations, we looked for alterations that occurred in 2 or more of the 14 samples subjected to whole-exome sequencing. From this analysis, as expected, the BRAF p.Val600Glu alteration was captured in 7 out of the 14 samples. In addition to BRAF, we found nine more genes harboring a recurrent mutation. Seven of the new recurrent mutations were non-synonymous and two were synonymous ( Table 1) . Further screening of the new hotspot mutations in an additional 153 melanomas identified DCC and ZNF831 to have a third recurring mutation each. Strikingly, TRRAP, encoding the transformation/transcription domain-associated protein, contained four additional cases that harbored the identical mutation ( Fig. 1 and Supplementary Fig. 2) , one of which we found in the commercially available melanoma cell line A375. The recurring mutation in TRRAP was a cytosine to thymine change at position 2,165 of the transcript (uc003upp.1), leading to a serine to phenylalanine substitution at amino acid residue 722 of the protein (p.Ser722Phe). The likelihood for the occurrence of six identical mutations is approximately 5 × 10 −20 , suggesting that the TRRAP hotspot mutation is important.
Subsequent sequence analysis of all coding exons of TRRAP in 25 additional melanomas revealed no additional non-synonymous alterations. The positions of the mutations in TRRAP imply that they are likely to be oncogenic, as we observed no truncating mutations, and 100% of the alterations occurred in one location. In addition, the affected residue is highly conserved evolutionarily ( Supplementary  Fig. 3 ). TRRAP functions as part of a multiprotein coactivator complex possessing histone acetyltranferase activity that is central to the transcriptional activity of p53, c-Myc and E2F1 (refs. 11,12) . To determine whether the TRRAP recurrent alteration (p.Ser722Phe) is transforming, we transiently transfected NIH 3T3 cells with empty vector, wildtype TRRAP, mutant TRRAP or oncogenic Ras with p.Gly12Val. Two weeks after transfection, mutant TRRAP transformed NIH 3T3 cells more efficiently than wild-type TRRAP (Fig. 2a) . Levels of TRRAP were comparable between the transfected cells ( Fig. 2b) .
To assess if melanoma cells harboring endogenous TRRAP mutations are dependent on TRRAP for survival, we used short hairpin RNA (shRNA) to stably knockdown TRRAP protein levels in melanoma cells harboring either wild-type TRRAP (SK-Mel-28 and 17T) or mutant Samples used in the exome capture and prevalance screen were obtained from the Surgery Branch, National Cancer Institute. Validation set 1 samples were obtained from The Division of Medical Oncology, University of Colorado Denver School of Medicine. A375 is a commercially available melanoma cell line. Listed BRAF mutations are from the whole-exome study only. Based on genome build hg18 (NCBI 36.1). Number of samples investigated: exome capture, n = 14; prevalence screen, n = 70; validation set 1, n = 39; validation set 2, n = 32; commercial cell lines, n = 12.
l e t t e r s TRRAP (63T and A375). We confirmed specific targeting of TRRAP by immunoblotting of transiently transfected HEK293T cells or one of the targeted melanoma cell lines (Fig. 2c,d ). We grew clones in 10% or 2.5% serum to test cell viability. Knockdown of TRRAP had minimal effect on the survival of cells expressing wild-type TRRAP but substantially increased apoptosis rates of melanoma lines carrying mutant TRRAP, particularly when the clones were grown in low serum (Fig. 2e-h and Supplementary Fig. 4 ). These results were corroborated by protein blot analysis, which showed increased levels of cleaved PARP, specifically in mutant cells knocked down for TRRAP as compared to vector control, as well as to TRRAP wild-type cells (Fig. 2i,j) . Thus, mutant TRRAP is essential for melanoma cell survival, which is consistent with previous results showing that TRRAP knockout mice are embryonic lethal 13 .
To further evaluate the prevalence and spectrum of somatic mutations in genes identified in the whole-exome discovery screen, we selected genes with more mutations than expected using the observed mutation rate (binomial P < 0.05; see Online Methods) (Supplementary Table 3 ) and those that were mutated in more than two discovery screen samples. We identified 16 such genes and analyzed them for mutations in an additional 38 melanoma samples using PCR amplification and Sanger sequencing. We identified a total of 65 putative changes in the prevalence screen ( Table 2) .
Notably, we found these sixteen genes, which, except for BRAF, had not previously been identified as playing a role in melanoma, to scale up and harbor an increasing number of somatic mutations in the prevalence screen. This correlated with the initial frequency identified in the discovery screen ( Table 2 and Supplementary Table 4 ). SIFT analysis predicted that a large fraction of the alterations would affect protein function (Supplementary Table 5) .
We found GRIN2A, which was mutated in 6 of the 14 melanomas in the discovery screen, to harbor an additional 11 somatic mutations in the prevalence screen. In addition to the discovery and prevalence Table 4 ). The number of C>T mutations identified in GRIN2A was significantly greater than the numbers of other nucleotide substitutions, resulting in a high prevalence of C>T/G>A transitions (P < 0.001) (Supplementary Fig. 5 ). Supplementary Figure 6 depicts the various genetic and analytic stages used in our study. GRIN2A, found on chromosome 16p13.2, encodes a glutamate (N-methyl-(D)-aspartic acid (NMDA)) receptor subunit ε-1 that is part of the class of ionotropic glutamate receptors and bears the agonist binding site for glutamate 14 . The location of the discovered GRIN2A alterations is summarized in Figure 3 . We observed two mutation clusters surrounding amino acids 371, 372 and 373 in the PBP1 iGluR NMDA NR2 domain and 1,073, 1,074 and 1,076 in the NMDAR2 C domain. In addition, we observed three recurrent alterations (p.Ser278Phe, p.GluE371Lys and p.Glu1175Lys). The affected residues within these clusters are highly conserved evolutionarily, and SIFT analysis predicts that over 51% would affect protein function (Supplementary Table 5 ). Furthermore, we identified five nonsense mutations.
The nature of somatic mutations in tumors may aid in classifying the identified genes as oncogenes or tumor suppressors 15 . Generally, oncogenes harbor adjacent missense recurrent mutations that affect one allele. Tumor suppressor genes are generally mutated throughout the gene; many of the mutations truncate the protein and generally affect both alleles. Based on this classification, the mechanism by which mutations in GRIN2A have a tumorigenic effect is unclear; however, their frequency strongly suggests that they play a major role in melanoma and are worthy of future investigation.
The comprehensive approach to acquiring data in this study provided an opportunity to investigate whether any particular new gene pathways have a role in melanoma (Online Methods). From this analysis, we found the glutamate signaling pathway to be highly significant. Glutamate is known to activate two different types of receptors: ionotropic glutamate receptors (iGluRs) and metabotropic glutamate receptors (mGluRs). iGluRs are ligand-gated ion channels that allow cations such as calcium and potassium to pass through the plasma membrane of the cell after the binding of glutamate to the receptors. iGluRs are subdivided into three receptor types according to agonists response, one of which is N-methyl-d-aspartate (NMDA) 16 . Thus, GRIN2A, the most highly mutated gene in our screen, encodes a glutamate receptor subunit that binds NMDA. Another highly mutated gene identified was PLCB4, which encodes a downstream protein involved in metabotropic glutamate receptor-related signal transduction causing inositol phosphate production and protein kinase C (PKC) activation 17 . Importantly, a recent genetic analysis of the G-protein coupled receptor family in melanoma identified that GRM3, a metabotropic glutamate receptor also activated by glutamate, is mutated in 16% of melanoma cases (Prickett, T.D. et al., unpublished data) . In this case as well, the GRM-signaling downstream effector PLCB4 is activated. Finally, a survey of the tyrosine kinome in melanoma has pointed to ERBB4, Pyk2 and the Ephrin receptors to be highly mutated 4 . Interestingly, ERBB4, its ligand NRG1, Pyk2 and the Ephrins have been shown to play a crucial role in modulation of NMDA receptor signaling [18] [19] [20] [21] . Thus, molecular and genetic studies have implicated crosstalk between NRG1-ERBB4, GRM3, Ephrin signaling and glutamate receptor functions. A link between the glutamate pathway and tumorigenesis has been seen in neuronal tumors, where glioma cells releasing an excess of glutamate showed more aggressive growth than parental glioma cells 22 . Furthermore, previous reports showing that expression of GRM1 results in melanocytes transformation 23, 24 also implicated glutamate signaling in melanoma. A glutamate pathway schematic summarizing these various components is depicted in Supplementary Figure 7 .
Our study presents, to our knowledge, the most complete analysis of melanoma exome alterations to date, thus allowing us to (i) identify TRRAP as an unexpected target of recurring genetic alterations, (ii) reveal genes that were not previously connected with melanoma, one of which, GRIN2A, is one of the most highly mutated in melanoma to date and (iii) show that a majority of melanoma tumors had alterations in genes encoding members of the glutamate signaling pathway.
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